000 01389 a2200325 4500
005 20250514010122.0
264 0 _c20011204
008 200112s 0 0 eng d
022 _a0924-977X
024 7 _a10.1016/s0924-977x(01)00100-6
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aKasper, S
245 0 0 _aPanic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors.
_h[electronic resource]
260 _bEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
_cAug 2001
300 _a307-21 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAnimals
650 0 4 _aAntidepressive Agents
_xtherapeutic use
650 0 4 _aBenzodiazepines
_xtherapeutic use
650 0 4 _aComorbidity
650 0 4 _aDepressive Disorder, Major
_xdrug therapy
650 0 4 _aHumans
650 0 4 _aPanic Disorder
_xdrug therapy
650 0 4 _aRandomized Controlled Trials as Topic
_xstatistics & numerical data
650 0 4 _aSerotonin
_xmetabolism
650 0 4 _aSelective Serotonin Reuptake Inhibitors
_xtherapeutic use
700 1 _aResinger, E
773 0 _tEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
_gvol. 11
_gno. 4
_gp. 307-21
856 4 0 _uhttps://doi.org/10.1016/s0924-977x(01)00100-6
_zAvailable from publisher's website
999 _c11456263
_d11456263